Cargando…
Molecular Targeted Therapies for the Treatment of Leptomeningeal Carcinomatosis: Current Evidence and Future Directions
Leptomeningeal carcinomatosis (LMC) is the multifocal seeding of cerebrospinal fluid and leptomeninges by malignant cells. The incidence of LMC is approximately 5% in patients with malignant tumors overall and the rate is increasing due to increasing survival time of cancer patients. Eradication of...
Autores principales: | Lee, Dae-Won, Lee, Kyung-Hun, Kim, Jin Wook, Keam, Bhumsuk |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964450/ https://www.ncbi.nlm.nih.gov/pubmed/27399673 http://dx.doi.org/10.3390/ijms17071074 |
Ejemplares similares
-
Recent Advancements of Treatment for Leptomeningeal Carcinomatosis
por: Gwak, Ho-Shin, et al.
Publicado: (2015) -
Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis
por: Park, Won-Young, et al.
Publicado: (2016) -
Leptomeningeal Carcinomatosis with Delayed Ocular Manifestations
por: Czyz, Craig, et al.
Publicado: (2021) -
Leptomeningeal carcinomatosis or ischemic cerebrovascular disease?
por: Eran, Ayelet, et al.
Publicado: (2021) -
Leptomeningeal carcinomatosis and breast cancer: a systematic review of current evidence on diagnosis, treatment and prognosis
por: Mollica, Ludovica, et al.
Publicado: (2021)